Apoptosis and proliferation related molecules (Bcl-2, Bax, p53, PCNA) in papillary microcarcinoma versus papillary carcinoma of the thyroid

References

• Li Volsi V A. Surgical Pathology of the Thyroid. Saunders, Philadelphia 1990
   Google Scholar
• Rosai J, Carcangiu M L, De Lellis R A. Tumors of the thyroid gland. Atlas of Tumor Pathology. Armed Forces Institute of Pathology, Washington, DC 1992; 161–182, Fascicle 5, 3rd Series
   Google Scholar
• Mizukami Y, Michigishi T, Nonomura A, Noguchi M, Nakamura T. Thyroid carcinoma: clinical, pathologic correlations. Crit Rev Oncol Hematol 1995; 18: 67–102
   PubMed Web of Science ®Google Scholar
• Mazzaferri E L, Jhiang S. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418–428
   PubMed Web of Science ®Google Scholar
• Gilliland F D, Hunt W C, Morris D M, Key C R. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from Surveillance, Epidemiology and END Results (SEER) program 1973–1991. Cancer 1997; 79: 564–573
   PubMed Web of Science ®Google Scholar
• Albores-Saavedra J A, Jianhua W. The many faces and mimics of papillary thyroid carcinomas. Endocrine Pathol 2006; 17: 1–18
   PubMed Web of Science ®Google Scholar
• Fleming I D, Cooper J S, Henson D E. Thyroid gland. American Joint Committee on Cancer. Cancer Staging Manual5th ed. Lippincott-Raven, Philadelphia 1997; 59–64
   Google Scholar
• Shah J P, Kian K, Forastiere A, et al. American Joint Committee on Cancer. Cancer Staging Manual6th ed. Springer-Verlag, New York 2002; 77–87
   Google Scholar
• Roti E, Rossi R, Transforini G, et al. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. J Clin Endocrinol Metab 2006; 91: 2171–2178
   PubMed Web of Science ®Google Scholar
• Piersanti M, Ezzat S, Asa S L. Controversies in papillary microcarcinoma of the thyroid. Endocrine Pathol 2003; 14: 183–192
   PubMed Web of Science ®Google Scholar
• Pelizzo M R, Boschin I M, Toniato A, et al. Papillary thyroid microcarcinoma (PTMC): prognostic factors, management and outcome in 403 patients. Eur J Surg Oncol 2006; 32: 1144–1148
   PubMed Web of Science ®Google Scholar
• Baloch Z W, Li Volsi V A. Microcarcinoma of the thyroid. Adv Anat Pathol 2006; 13: 69–75
   PubMed Web of Science ®Google Scholar
• Rubin L I, Philpott Ki, Brooks S F. The cell cycle and cell death. Curr Biol 2003; 3: 391–394
   Web of Science ®Google Scholar
• Mikulski S M. Pathogenesis of cancer in view of mutually opposing apoptotic and anti-apoptotic growth signals. Int J Oncology 1994; 4: 1257–1263
   PubMed Web of Science ®Google Scholar
• Mathew R, White E. FLIPping the balance between apoptosis and proliferation in thyroid cancer. Clin Canc Res 2006; 12: 3648–3651
   PubMed Web of Science ®Google Scholar
• Kirkin V, Joos S, Zörnig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004; 1644: 229–249
   PubMed Web of Science ®Google Scholar
• Levine A J, Momand J, Finlay C A. The p53 tumor suppressor gene. Nature 1991; 351: 453–456
   PubMed Web of Science ®Google Scholar
• Fridman J S, Lowe W. Control of apoptosis by p53. Oncogene 2003; 22: 9030–9040
   PubMed Web of Science ®Google Scholar
• Reed J C. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124: 1–6
   PubMed Web of Science ®Google Scholar
• LiVolsi V A, Albores-Saavedra J, Asa S, . Papillary carcinoma. Pathology and Genetics. Tumours of Endocrine Organs, DeLellis RA, Lloyd RV, Heitz U, Eng C, et al. World Health Organization, IARC Press, Lyon 2004
   Google Scholar
• Horie S, Maeta H, Endo K, Ueta T, Takashima K, Terada T. Overexpression of p53 protein and MDM2 in papillary carcinomas of the thyroid: correlations with clinicopathological features. Pathol Int 2001; 51: 11–15
   PubMed Web of Science ®Google Scholar
• Preto A, Reis-Filho J S, Ricardo S, Soares P. P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression. Pathol Res Pract 2002; 198: 449–454
   PubMed Web of Science ®Google Scholar
• Gross A, McDonell J M, Korsmeyer S J. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899–1911
   PubMed Web of Science ®Google Scholar
• Pilotti S, Collini P, Rilke F, Cattoreti G, Del Bo R, Pierotti M A. Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol 1994; 172: 337–342
   PubMed Web of Science ®Google Scholar
• Branet F, Brousset P, Krajewski S, et al. Expression of the cell death-inducing gene Bax in carcinomas developed from the follicular cells of the thyroid gland. J Clin Endocrinol Metab 1996; 81: 2726–2730
   PubMed Web of Science ®Google Scholar
• Pollina L, Pacini F, Fontanini G, Vignati S, Bevilacqua G, Basolo F. Bcl-2, p53 and proliferating cell nuclear antigen expression are related to the degree of differentiation in thyroid carcinomas. Br J Cancer 1996; 73: 139–143
   PubMed Web of Science ®Google Scholar
• Manetto V, Lorenzini R, Cordon-Cardo C, et al. Bcl-2 and Bax expression in thyroid tumours. An immunohistochemical and western blot analysis. Virchows Arch 1997; 430: 125–130
   PubMed Web of Science ®Google Scholar
• Moore D, Ohene-Fianko D, Garcia B, Chakrabarti S. Apoptosis in thyroid neoplasms: relationship with p53 and Bcl-2 expression. Histopathology 1988; 32: 35–42
   Google Scholar
• Mitselou A, Peschos D, Dallas P, Charalabopoulos K, Agnantis N J, Vougiouklakis T. Immunohistochemical analysis of expression of Bcl-2 protein in papillary carcinomas and papillary microcarcinomas of the thyroid gland. Exp Oncol 2004; 26: 282–286
   PubMed Web of Science ®Google Scholar
• Aksoy M, Giles Y, Kapran Y, Terzioglu T, Tezelman S. Expression of Bcl-2 in papillary thyroid cancers and its prognostic value. Acta Chir Belg 2005; 105: 644–648
   PubMed Web of Science ®Google Scholar
• Ito Y, Uruno T, Takamura Y, et al. Papillary microcarcinomas of the thyroid with preoperatively detectable lymph node metastasis show significantly higher aggressive characteristics on immunohistochemical examination. Oncology 2005; 68: 87–96
   PubMed Web of Science ®Google Scholar
• Siironen P, Nordling S, Louhimo J, Haapiainen R, Haglund C. Immunohistochemical expression of Bcl-2, ki-67, and p21 in patients with papillary thyroid cancer. Tumour Biol 2005; 26: 50–56
   PubMedGoogle Scholar
• Hermann S, Sturm I, Mrozek I, et al. Bax expression in benign and malignant thyroid tumours: dysregulation of wild type p53 is associated with a high Bax and p21 expression in thyroid carcinoma. Int J Cancer 2001; 92: 805–811
   PubMed Web of Science ®Google Scholar
• Karlidag T, Cobanoglu B, Keles E, et al. Expression of Bax, p53 and p27/kip in patients with papillary thyroid carcinoma with or without cervical nodal metastasis. Am J Otolaryngol 2007; 28: 31–36
   PubMed Web of Science ®Google Scholar
• Sugitani I, Yanagisava A, Shimizu A, Kato M, Fujimoto Y. Clinicopathologic and immunohistochemical studies of papillary thyroid microcarcinoma presenting with cervical lymphadenopathy. World Surg 1998; 22: 731–737
   PubMed Web of Science ®Google Scholar
• Chen B-K, Ohtsuki Y, Furihata M, et al. Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage. Int J Oncol 1999; 15: 893–898
   PubMed Web of Science ®Google Scholar
• Corapcioglu D, Sak D S, Delibasi T, et al. Papillary microcarcinoma of the thyroid gland and immunohistochemical analysis of expression of p53 protein in papillary microcarcinomas. J Translat Med 2006; 4: 28–33
   PubMed Web of Science ®Google Scholar